Cincor Pharma, Inc.

CINCCIK 0001868734 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K filed Mar 22, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:No prior 10-KFull-doc fallback

Full filing:tone -0.0162

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Cincor Pharma, Inc.

Name	Roles	Filings
Pearce Catherine	Officer	6
Allison David D.	Director	3
Freeman Mason	Officer	3
De Garidel Marc	OfficerDirector	3
5am Opportunities I (Gp), LLC	10% Owner	2

Showing 1-5 of 40

Per pagePage 1 of 8Next

All filings

31 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Feb 28, 2023	5am Partners VI, LLC 10% Owner	UTender	3,953,990	-	-
Feb 27, 2023	Freeman Mason Chief Medical Officer	SSale	6	$15.21	$91
Feb 27, 2023	Healy James Director · 10% Owner	SSale	6,000	$14.32	$85,920
Feb 24, 2023	De Garidel Marc Chief Executive Officer · Director	UTender	12,500	-	-
Feb 24, 2023	Thero John F Director	Holdings only	-	-	-

Showing 1-5 of 31

Per pagePage 1 of 7Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value